目的：：观察总结复方玄驹胶囊与索利那新联合治疗Ⅲ型前列腺炎患者的临床疗效。方法：将确诊为Ⅲ型前列腺炎患者128例随机分为对照组和观察组,每组各64例。对照组患者给予口服左氧氟沙星片0.4 g治疗,1次/d；观察组患者在对照组治疗的基础上给予复方玄驹胶囊(1.24 g/次,3次/d)和索利那新(5 mg /次,1次/晚)治疗。两组患者均给药4周为1个疗程。1个疗程治疗前后,观察两组患者的国际慢性前列腺炎症状指数(NIH-CPSI)评分变化和临床疗效。结果：治疗后,两组患者的NIH-CPSI 评分较治疗前明显改善(P<0.05)；观察组患者的临床治疗总有效率为85.94%,对照组为68.75%；观察组患者的临床疗效优于对照组(P<0.05)。结论：复方玄驹胶囊与索利那新联合治疗Ⅲ型前列腺炎患者的临床效果显著,值得推广使用。%Objective:To observe clinical efficacy of compound Xuanju capsule combined with Solifenacin in treatment of type III prostatitis. Methods:128 cases with type III prostatitis were selected as study subjects. The patients were randomly divided into control group (64 cases) and observation group (64 cases). The control group orally tookLevofloxacin tablets 0. 4g at 1 time/d, while the observation group was treated with Levofloxacin tablets 0. 4g at 1 time/d, compound Xuanju capsule 1. 24g/time at 3 times/d, and Solifenacin 5 mg/time at 1 timeight. It took 4 weeks as a course. The change of chronic prostatitis symptom index ( NIH-CPSI) be-fore and after the treatment and the clinical curative effects of the two groups were observed. Results:The NIH-CPSI scores in the two groups after the treatment were significantly improved than those before the treatment (P<0. 05). The total effective rates of control group and observation group were 68. 75% and 85. 94%, respectively; and the clinical efficacy of observation group was superior to that of control group (P<0. 05). Conclusions:Compound Xuanju Capsule combined with Solifenacin in the treatment of type III pros-tatitis has a significant clinical efficacy, and is worthy of promotion.
展开▼
